We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

2 Apr 2019 09:23

RNS Number : 8195U
Faron Pharmaceuticals Oy
02 April 2019
 

TR-1: Standard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Oy

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

 

Chase (GA Group) Nominees Limited 963,938*

HSBC Global Custody Nominee (UK) Limited

284,539*

State Street Nominees Limited 8,365*

*denotes direct interest

BNY (Nominees) Limited 30,420

 

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

29/03/2019

6. Date on which issuer notified (DD/MM/YYYY):

01/04/2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.63%

 

3.63%

35,476,519

Position of previous notification (if

applicable)

4.86%

0.03%

4.89%

 

        

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesFI4000153309

1,256,842

30,420

3.54%

0.09%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

1,287,262

3.63%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

 

 

 

Aviva Group Holdings Limited

 

 

 

Aviva Investors Holdings Limited

 

 

 

Aviva Investors Global Services Limited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

This notification is prompted by a 4% to 3% change at Combined Interest Level

 

 

     

 

Place of completion

Norwich, England

Date of completion

01 APRIL 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLVLLBBKZFFBBV
Date   Source Headline
18th Apr 20174:17 pmRNSPurchase of Shares
18th Apr 20177:00 amRNSCollaboration with Birmingham University
13th Apr 20171:43 pmRNSPurchase of Shares
4th Apr 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSFinal Results 2016
27th Mar 20179:23 amRNSHolding(s) in Company
21st Mar 201711:05 amRNSSecond Price Monitoring Extn
21st Mar 201711:00 amRNSPrice Monitoring Extension
7th Mar 201710:54 amRNSHolding(s) in Company
7th Mar 20177:00 amRNSNotice of Full Year Results
3rd Mar 201711:02 amRNSHolding(s) in Company
1st Mar 20172:05 pmRNSSecond Price Monitoring Extn
1st Mar 20172:00 pmRNSPrice Monitoring Extension
1st Mar 201711:35 amRNSResult of Placing & Subscription & Issue of Equity
28th Feb 20177:00 amRNSProposed Placing and Subscription
20th Feb 20177:00 amRNSFirst Patient Recruited in Phase II RAAA Study
9th Feb 20177:00 amRNSFaron update for 2017
9th Dec 20161:05 pmRNSNotification of Major Interest in Shares
9th Dec 20161:00 pmRNSNotification of Major Interest in Shares
5th Dec 20167:00 amRNSPDMR Shareholding
21st Nov 20167:00 amRNSGrant of options
31st Oct 20167:00 amRNSNew Application Accepted by Finnish Patent Office
24th Oct 20167:00 amRNSFirst patient recruited in Japanese Ph III trial
7th Oct 20161:41 pmRNSNotification of Major Interest in Shares
6th Oct 201610:00 amRNSNotification of Major Interest in Shares
5th Oct 20165:10 pmRNSNotification of Major Interest in Shares
26th Sep 20163:59 pmRNSDirector Dealing
21st Sep 201611:27 amRNSRaises £8.0 M through a Placing and Subscription
20th Sep 20167:00 amRNSProposed Placing & Subscription to raise £8M
5th Sep 20167:00 amRNSInterim Results for six months ended 30 June 2016
10th Aug 20167:00 amRNSFaron Pharmaceuticals Notice of Interim Results
25th Jul 20167:00 amRNSFaron enters agreement with Abzena for Clevegen
22nd Jun 201612:00 pmRNSFaron to Present at Proactive Investors Forum
14th Jun 20167:00 amRNSFaron Provides Update at R&D Day
13th Jun 20167:00 amRNSFaron Licenses Traumakine Rights to Pharmbio Korea
26th May 201610:53 amRNSFaron Result of Annual General Meeting
26th May 20167:00 amRNSFaron Expands R&D Strategy for Clevegen
13th May 20167:00 amRNSFaron Pharmaceuticals Ltd to host an R&D Day
4th May 20167:00 amRNSNotice of AGM
3rd May 20167:00 amRNSFaron Appoints New Medical Director
22nd Apr 20167:00 amRNSFaron Appoints Panmure Gordon as Joint Broker
19th Apr 20167:00 amRNSFaron Files Two New Patents to Protect Clevegen
10th Mar 20167:00 amRNSAnnual Results for the year ended 31 December 2015
1st Mar 20167:00 amRNSFaron files patent application for Traumakine
10th Feb 20167:00 amRNSNotice of Preliminary Results
7th Jan 20167:00 amRNSTop-line results from Japanese study of Traumakine
29th Dec 20157:00 amRNSFirst Patient recruited in Phase III ARDS Study
21st Dec 20157:00 amRNSFaron Awarded ?1.5 million Tekes Funding
30th Nov 20157:00 amRNSKey Publication in Journal of Immunology
17th Nov 20157:30 amRNSAdmission to AIM and first day of dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.